HRP20171859T1 - Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale - Google Patents

Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale Download PDF

Info

Publication number
HRP20171859T1
HRP20171859T1 HRP20171859TT HRP20171859T HRP20171859T1 HR P20171859 T1 HRP20171859 T1 HR P20171859T1 HR P20171859T T HRP20171859T T HR P20171859TT HR P20171859 T HRP20171859 T HR P20171859T HR P20171859 T1 HRP20171859 T1 HR P20171859T1
Authority
HR
Croatia
Prior art keywords
hydrogen
image
co2ch3
och2ch3
co2h
Prior art date
Application number
HRP20171859TT
Other languages
English (en)
Croatian (hr)
Inventor
Eric Anderson
Gary L. Bolton
Bradley Caprathe
Xin Jiang
Chitase Lee
William H. Roark
Melean Visnick
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of HRP20171859T1 publication Critical patent/HRP20171859T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20171859TT 2010-12-17 2011-12-19 Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale HRP20171859T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424601P 2010-12-17 2010-12-17
PCT/US2011/065897 WO2012083306A2 (en) 2010-12-17 2011-12-19 Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP11807826.0A EP2651902B1 (en) 2010-12-17 2011-12-19 Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Publications (1)

Publication Number Publication Date
HRP20171859T1 true HRP20171859T1 (hr) 2018-01-26

Family

ID=45470714

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171859TT HRP20171859T1 (hr) 2010-12-17 2011-12-19 Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale

Country Status (32)

Country Link
US (6) US8513436B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2651902B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5857068B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102000301B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103596929B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR084353A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011343466B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112013015241B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2822071C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2013001754A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO6910185A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1120032T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2651902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA025568B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2653717T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20171859T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE038046T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL226923A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2651902T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2013006902A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2651902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ612788A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2651902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2651902T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS56795B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG191181A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2651902T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201800069T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI527788B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2012083306A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201305060B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
EP2279196B1 (en) 2008-04-18 2015-01-21 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
EP2651902B1 (en) 2010-12-17 2017-11-08 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
MX338210B (es) 2010-12-17 2016-04-07 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin -4-il-fenil)-n4-[2- (propan-2-sulfonil)-fenil]-pirimidin-2,4-diami na.
MX387999B (es) 2012-04-27 2025-03-19 Reata Pharmaceuticals Holdings Llc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos.
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
MX372772B (es) * 2014-01-24 2020-06-29 Reata Pharmaceuticals Inc Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
CN107428698B (zh) * 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
EP3538104A1 (en) 2016-11-08 2019-09-18 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11286226B2 (en) 2017-09-21 2022-03-29 Northwestern University Polycyclic carbogenic molecules and uses thereof as anti-cancer agents
US11465963B2 (en) * 2017-11-21 2022-10-11 Biogen Ma Inc. Tetrahydronaphthalene derivatives useful as Nrf2 activators
CA3103726A1 (en) * 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20250025465A1 (en) * 2021-11-17 2025-01-23 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma
WO2024255851A1 (en) * 2023-06-16 2024-12-19 Nanjing Curegene Technology Co., Ltd. Tumor-specific expression cassette and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875201A (en) 1957-08-28 1959-02-24 Searle & Co Dehydrotigogenone intermediates
US3071577A (en) * 1959-08-13 1963-01-01 Syntex Corp Pyrimidinyl androstanes
US3994935A (en) 1975-11-24 1976-11-30 E. R. Squibb & Sons, Inc. Steroidal 16β-alkyl[16α,17-b]naphthalenes
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
CN1013672B (zh) * 1983-10-03 1991-08-28 美国辉瑞有限公司 2-氨基-5-羟基-4-甲基嘧啶衍生物的制备方法
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
JPH08208479A (ja) * 1994-04-29 1996-08-13 Takeda Chem Ind Ltd クラビンアルカロイド誘導体を含有する鎮痛剤
WO1995029912A1 (en) 1994-04-29 1995-11-09 Takeda Chemical Industries, Ltd. Ergoline derivatives as analgesics
CA2199474C (en) * 1994-09-09 2011-06-21 Shozo Koyama Inhibitory or blocking agents of molecular generating and/or inducing functions
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6365768B1 (en) 1999-05-14 2002-04-02 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
HK1048592A1 (zh) 2000-02-14 2003-04-11 Merck & Co., Inc. 雌激素受体调节剂
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
WO2002026762A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
ES2369837T3 (es) * 2000-12-28 2011-12-07 Ono Pharmaceutical Co., Ltd. Compuestos triheterocíclicos como antagonistas de receptor cfr.
AU2002308701A1 (en) 2001-05-14 2002-11-25 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
EP1418900A4 (en) 2001-08-13 2006-01-25 Merck & Co Inc SELECTIVE ESTROGEN RECEPTOR MODULATORS
AR037090A1 (es) 2001-09-19 2004-10-20 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de inflamaciones
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
WO2003059339A1 (en) 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2003062260A1 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
EP1579186A4 (en) 2002-03-21 2008-10-08 Sunesis Pharmaceuticals Inc IDENTIFYING KINASE INHIBITORS
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
CN1845750B (zh) 2003-09-02 2014-05-07 尤尼根公司 用于预防及治疗认知衰退和年龄相关的记忆障碍的无取代b环类黄酮和黄烷混合物的组合物
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
WO2006089406A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
JP2008537544A (ja) 2005-03-17 2008-09-18 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ アブラインビルアミド、ステファシジンｂおよびそれらのアナログの合成
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
US20070232577A1 (en) 2006-03-23 2007-10-04 Advanced Life Sciences, Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
WO2008000070A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
SI2252283T1 (sl) 2008-01-11 2019-02-28 Reata Pharmaceuticals, Inc. Sintetični triterpenoidi in postopki uporabe pri zdravljenju bolezni
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
EP2279196B1 (en) * 2008-04-18 2015-01-21 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009237581C1 (en) 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
WO2009134726A1 (en) 2008-04-28 2009-11-05 Abbott Laboratories Substituted pyrimidine derivatives as histamine h4 receptor ligands
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
SI2558105T1 (sl) 2010-04-12 2020-02-28 Reata Pharmaceuticals, Inc. Bardoksolon metil za zdravljenje debelosti
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
KR20140017520A (ko) 2010-12-17 2014-02-11 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 아조사이클릭 아미드
EP2651902B1 (en) 2010-12-17 2017-11-08 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PH12013501528A1 (en) 2011-01-31 2013-09-16 Bristol Myers Squibb Co C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
ES2729405T3 (es) 2011-03-11 2019-11-04 Reata Pharmaceuticals Inc Derivados triterpenoides de C4-monometilo y métodos de uso de los mismos
MX387999B (es) 2012-04-27 2025-03-19 Reata Pharmaceuticals Holdings Llc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos.
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MX380589B (es) 2013-08-23 2025-03-12 Reata Pharmaceuticals Holdings Llc Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxolona o sus análogos.

Also Published As

Publication number Publication date
JP2014501250A (ja) 2014-01-20
LT2651902T (lt) 2018-01-10
RS56795B1 (sr) 2018-04-30
US20220281807A1 (en) 2022-09-08
US20160130220A1 (en) 2016-05-12
US20200207706A1 (en) 2020-07-02
US20180265455A1 (en) 2018-09-20
NO2651902T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-04-07
CO6910185A2 (es) 2014-03-31
HK1189595A1 (zh) 2014-06-13
CN103596929B (zh) 2016-10-19
JP5857068B2 (ja) 2016-02-10
SMT201800069T1 (it) 2018-03-08
TWI527788B (zh) 2016-04-01
CL2013001754A1 (es) 2013-11-29
SI2651902T1 (en) 2018-02-28
EP2651902B1 (en) 2017-11-08
US20120196880A1 (en) 2012-08-02
AU2011343466B2 (en) 2017-01-05
US11814338B2 (en) 2023-11-14
CA2822071A1 (en) 2012-06-21
TW201249785A (en) 2012-12-16
EP2651902A2 (en) 2013-10-23
AR084353A1 (es) 2013-05-08
WO2012083306A2 (en) 2012-06-21
PL2651902T3 (pl) 2018-04-30
US8513436B2 (en) 2013-08-20
ME02973B (me) 2018-07-20
BR112013015241B1 (pt) 2022-03-29
PT2651902T (pt) 2018-02-01
DK2651902T3 (en) 2018-01-08
US9884809B2 (en) 2018-02-06
US9174941B2 (en) 2015-11-03
CN103596929A (zh) 2014-02-19
CA2822071C (en) 2019-07-16
ZA201305060B (en) 2016-07-27
AU2011343466A1 (en) 2013-07-25
CY1120032T1 (el) 2018-12-12
IL226923A (en) 2016-06-30
SG191181A1 (en) 2013-07-31
KR20130130784A (ko) 2013-12-02
EA025568B1 (ru) 2017-01-30
US20140051739A1 (en) 2014-02-20
KR102000301B1 (ko) 2019-07-15
BR112013015241A2 (pt) 2021-04-20
ES2653717T3 (es) 2018-02-08
NZ612788A (en) 2015-10-30
HUE038046T2 (hu) 2018-09-28
MX2013006902A (es) 2013-10-17
WO2012083306A3 (en) 2012-10-11
EA201390894A1 (ru) 2013-12-30
US11192852B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
HRP20171859T1 (hr) Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
RS53469B (en) Androgen receptor modulating compounds
RS51450B (en) 11-BETA-HYDROXISTEROID DEHYDROGENENE INHIBITORS 1
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
MX2008000115A (es) Derivados de piperidina utiles como antagonistas de histamina h3.
AR064319A1 (es) Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
AR051469A1 (es) Derivados de indol tetraciclicos como agentes antiviricos
DOP2011000061A (es) Compuestos de pirrol
WO2009022702A1 (ja) ピリピロペン誘導体の製造法およびその製造中間体
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
ECSP099639A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa
TN2010000136A1 (en) Composition comprising sphingosine 1 phosphate (s1p) receptor modulators
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
WO2007002559A8 (en) Pyrazole based lxr modulators
AR056470A1 (es) Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa
ATE555101T1 (de) Neue benzothiazepin- und benzothiepinverbindungen
RS52812B (en) PYROLIDIN-2-DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
HRP20160641T1 (hr) Fuzionirani triciklički spojevi kao inhibitori raf kinaze
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
AR068047A1 (es) Derivados de imidazol como moduladores de gamma secretasa. composiciones farmaceuticas.
HRP20140501T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
CA2666258A1 (en) Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure
AR074862A1 (es) Derivados de heterociclo biciclicos y sus metodos de uso